The Transmembrane Sequence of Human Histocompatibility  Leukocyte Antigen (HLA)-C as a Determinant in Inhibition  of a Subset of Natural Killer Cells by Davis, Daniel M. et al.
 
1265
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/99/04/1265/10 $2.00
Volume 189, Number 8, April 19, 1999 1265–1274
http://www.jem.org
 
The Transmembrane Sequence of Human Histocompatibility 
Leukocyte Antigen (HLA)-C as a Determinant in Inhibition 
of a Subset of Natural Killer Cells
 
By Daniel M. Davis, Ofer Mandelboim, Isabel Luque, Eishi Baba, 
Jonathan Boyson, and Jack L. Strominger
 
From the Department of Molecular and Cellular Biology, Harvard University, Cambridge, 
Massachusetts 02138
 
Summary
 
Molecular interactions with the extracellular domains of class I major histocompatibility com-
plex proteins are major determinants of immune recognition that have been extensively studied
both physically and biochemically. However, no immunological function has yet been placed
on the transmembrane or cytoplasmic amino acid sequences of these proteins despite strict con-
servation of unique features within each class I major histocompatibility complex locus. Here
we report that lysis by a subset of natural killer (NK) cells inhibited by target cell expression
of human histocompatibility leukocyte antigen (HLA)-Cw6 or -Cw7 was not inhibited by ex-
pression of chimeric proteins consisting of the extracellular domains of HLA-C and the
COOH-terminal portion of HLA-G. Assays using transfectants expressing a variety of HLA-
Cw6 mutants identified the transmembrane sequence and, in particular, cysteine at position
309 as necessary for inhibition of 68% (25/37) of NK cell lines and 23% (33/145) of NK clones
tested. Moreover, these NK clones inhibited by target cell expression of HLA-Cw6 and depen-
dent upon the transmembrane sequence were found not to express or to only dimly express
NK inhibitory receptors (NKIR1) that are EB6/HP3E4-positive. Furthermore, assays using
monoclonal antibody blocking suggest that an NK receptor other than NKIR1 or CD94 is re-
sponsible for recognition dependent upon the transmembrane sequence of HLA-Cw6.
Key words: NK cells • class I MHC protein • transmembrane sequence • NK receptors • 
cysteine
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K cells are lymphocytes that provide innate immunity
by killing virally infected or tumor cells apparently
independently of prior specific antigen stimulation (1).
Reduced or absent cell surface expression of class I MHC
proteins, which occurs, for example, in virally infected or
tumor cells deficient in class I MHC heavy chain 
 
b
 
2
 
-micro-
globulin (
 
b
 
2
 
m)
 
1
 
 or transporter associated with antigen pro-
cessing (TAP) gene expression, is one factor that renders a
cell susceptible to NK cell–mediated lysis. Thus, NK cells
survey target cells for absence of self class I MHC proteins,
the missing self hypothesis (2, 3), although absent or low
class I MHC protein expression is not always necessary or
sufficient for susceptibility to NK cell–mediated lysis (4).
NK cells express a wide variety of receptors for class I
MHC proteins that are capable of inhibiting or augmenting
NK cell cytotoxicity. In particular, 58-kD and 70-kD natu-
ral killer inhibitory receptors (NKIR) for class I MHC pro-
teins, containing two and three Ig domains, respectively, in-
hibit NK cell cytotoxicity (5–7), whereas related 50-kD
receptors associated with DAP12 (8) augment NK cell cyto-
toxicity (9). Other receptors from the Ig superfamily have
also been identified (10–14). The C-type lectin complex
CD94/NKG2A, or C, can also transduce inhibitory or co-
stimulatory signals, respectively, in NK cells (15) upon rec-
ognition of HLA-E (16–18). At least some of these recep-
tors can also regulate the activation of a subset of T cells
(19, 20). The repertoire of NK receptors expressed can
vary considerably among different donors (21, 22), and the
mechanisms by which such a multitude of receptors inter-
act in the regulation of NK cell cytotoxicity remain unclear
(23–25). Whether only the extracellular portions of class I
MHC proteins are sufficient to facilitate inhibition of NK
cell cytotoxicity by initiating signaling through these recep-
tors, or whether class I MHC proteins can play a more ac-
tive role in NK cell inhibition, e.g., by directly signaling
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b
 
2
 
m, 
 
b
 
2
 
-microglobulin; GPI, glycosyl-
phosphatidylinositol; NKIR, natural killer cell inhibitory receptor. 
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within target cells or by association with other target cell
surface proteins, has been little studied.
NKIR enable NK cells to be inhibited only by interac-
tion with particular class I MHC allotypes. In contrast,
HLA-G, a class Ib (nonclassical) MHC protein expressed at
the maternal–fetal interface (26), can be involved in inhibi-
tion of NK cells of diverse phenotypes (27). In part to search
for the mechanism facilitating the ability of HLA-G to in-
hibit NK cell cytotoxicity, the strikingly short cytoplasmic
tail and distinct transmembrane region of HLA-G compared
with that of HLA-C was investigated. To this end, con-
structs were made encoding mutants of HLA-C or chimeric
proteins made from extracellular portions of HLA-C with
the cytoplasmic tail and/or transmembrane region of HLA-G
and transfected into the B cell line 721.221, deficient in cell
surface expression of class I MHC protein. Transfectants
were then tested for their susceptibility to lysis by various
NK cell lines and clones. These studies unexpectedly led to
the delineation of a role for the transmembrane region in
the inhibitory function of HLA-C with respect to a subset
of human NK cells.
 
Materials and Methods
 
Plasmids Encoding Wild-Type, Chimeric, and Mutant Class I MHC
Proteins and Cell Transfectants. 
 
Plasmids containing wild-type
genes encoding HLA-C and -G proteins were used as described
(27, 28). Plasmids encoding chimeric HLA-Cw6 or HLA-Cw7
with the region encoding the conserved residue Arg 201 (near
the beginning of the 
 
a
 
3 domain) to the end of the mature protein
replaced by that of HLA-G were also prepared as described (29).
Proteins encoded by these plasmids were termed HLA-Cw6/
G-tail and HLA-Cw7/G-tail in the investigation of their relative
turnover at the cell surface (29), but in the current report, they
are renamed HLA-Cw6/G end and HLA-Cw7/G end to em-
phasize that these proteins contain part of the 
 
a
 
3 domain and the
complete transmembrane sequence as well as the cytoplasmic tail
of HLA-G (Fig. 1).
Plasmid inserts encoding HLA-Cw6 truncated by the insertion
of a stop codon were obtained by PCR from the plasmid encod-
ing HLA-Cw6 in pcDNA3 and cloned back into pcDNA3
(Invitrogen Corp.) as KpnI–EcoRI fragments. The primers used
for the PCR were 5
 
9
 
-GGGGTACCCCGCCGCCACCAT-
GCGGGTCATGGCGCCCCGAACC-3
 
9
 
 for the 5
 
9
 
 end of
HLA-Cw6, including an added KpnI restriction site and the
Kozak sequence to enhance expression, coupled with each of the
following for the 3
 
9
 
 end encoding the EcoRI restriction site and
stop codon (underlined): 5
 
9
 
-CCGGAATTCTCATCCACCTGA-
GCTCTTCCT-3
 
9
 
 for HLA-Cw6/315 stop, 5
 
9
 
-CCGGAAT-
TCTCACGCAGCCTGAGAGCAGCT-3
 
9
 
 for HLA-Cw6/325
stop, 5
 
9
 
-CCGGAATTCTCAGCCCTGGGCACTGTTGCT-3
 
9
 
for HLA-Cw6/332 stop, and 5
 
9
 
-CCGGAATTCTCACTCAT-
CAGAGCCCTGGGC-3
 
9
 
 for HLA-Cw6/335 stop.
To obtain the plasmid encoding HLA-Cw6 with cysteine at
position 309 replaced by tryptophan, the residue in that position
in HLA-A and HLA-G, two overlapping fragments were obtained
by PCR using the plasmid encoding HLA-Cw6 in pcDNA3 as the
template. The 5
 
9
 
 fragment was obtained using a T7 oligo (New
England Biolabs, Inc.) as the 5
 
9
 
 primer together with 5
 
9
 
-GCT-
CTTCCTCCTCCACATCACAAC-3
 
9
 
, and the 3
 
9
 
 fragment was
obtained using an SP6 oligo (New England Biolabs, Inc.) as the
3
 
9
 
 primer together with 5
 
9
 
-GTTGTGATGTGGAGGAGGAA-
GACC-3
 
9
 
. These two fragments were joined by PCR using SP6
and T7 oligos as primers and cloned into pcDNA3 as a KpnI–EcoRI
fragment.
The plasmid encoding HLA-Cw6 in which the transmem-
brane sequence had been replaced by that of HLA-G was made
by using three fragments obtained by PCR from the plasmids en-
coding HLA-Cw6 and HLA-G. The 5
 
9
 
 fragment encoding the
cytoplasmic tail of HLA-Cw6 was obtained by PCR using SP6 as
the 5
 
9
 
 primer together with 5
 
9
 
-GCTGCTGTGCTGTGGAG-
GAGGAAGAGCTCA-3
 
9
 
. The fragment encoding the transmem-
brane domain of HLA-G was obtained by PCR using 3
 
9
 
-TGA-
GCTCTTCCTCCTCCACAGCACAGCAGC-5
 
9
 
 at the 3
 
9
 
 end
and 5
 
9
 
-CTGAGATGGGAGCCATCTTCCCTGCCCACC-5
 
9
 
at the 5
 
9
 
 end. These two fragments were then joined together by
PCR using the appropriate flanking primers, producing a frag-
ment encoding the cytoplasmic tail of HLA-Cw6 attached to the
transmembrane domain of HLA-G. The 3
 
9
 
 fragment encoding
the extracellular portion of HLA-Cw6 was obtained by PCR
with T7 as the 3
 
9
 
 primer together with 5
 
9
 
-GGTGGGCAGG-
GAAGATGGCTCCCATCTCAG-3
 
9
 
. This fragment was then
joined to the fragment encoding the cytoplasmic tail of HLA-
Cw6 and transmembrane domain of HLA-G by PCR using T7
and SP6 oligos as primers. This insert was then cloned as a KpnI–
EcoRI fragment into pcDNA3. All primers were purchased from
Life Technologies and all plasmid inserts were sequenced by the
Core Facilities, Dana-Farber Cancer Institute (Boston, MA) using
T7, SP6, and primers internal to the class I MHC–encoded region.
The human B cell line 721.221, deficient in cell surface ex-
pression of class I MHC proteins (30), was obtained from the
American Type Culture Collection (ATCC). 721.221 cells were
transfected with 100 
 
m
 
g of linearized plasmids by electroporation
as described (28) and continually kept in the selection medium.
Figure 1. Alignment of amino acid sequences of HLA-Cw6, -Cw7,
-G, -A2, and the chimera HLA-Cw6/TM G used in the current study.
The location of the Bsu36I restriction site used to make the chimeras
HLA-Cw6/G end and HLA-Cw7/G end is marked. Residues underlined
were those mutated into stop codons in HLA-Cw6, and the cysteine at
position 309 that was mutated into tryptophan is marked bold and under-
lined. The region of HLA-Cw6 altered to make HLA-Cw6/TM G is
shaded. 
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Transfectants were sorted by flow cytometry to express equiva-
lent levels of class I MHC protein detected by the conformation-
specific mAb W6/32 (31). An exception, however, was that the
cell surface expression of class I MHC protein in the HLA-G
transfectant used was significantly higher than that of the other
transfectants, as shown to be necessary for inhibition of NK cell
cytotoxicity (27, 32).
Transfectants expressing the extracellular portions of HLA-C
also expressed equivalent levels of the epitope for mAb L31 by
flow cytometry. This mAb recognizes naturally occurring HLA-C
heavy chains not associated with 
 
b
 
2
 
m (33). Transfectants were
routinely stained with mAb W6/32 or G46-2.6 and analyzed by
flow cytometry to ensure that equivalent cell surface expression
of class I MHC proteins remained after time in culture. Transfec-
tants also expressed equivalent levels of proteins previously found to
be associated with class I MHC proteins (see Discussion), namely,
CD20, CD45, CD53, CD81, CD82, HLA-DR, and IL-2R 
 
g
 
chain as determined by flow cytometry using appropriate anti-
bodies. Expression of correctly sized heavy chains from HLA-Cw6,
-Cw7, -G, -Cw6/G end, and -Cw7/G end associated with the
light chain 
 
b
 
2
 
m was confirmed by immunoprecipitation from the
transfectants with mAb BBM.1 that recognizes 
 
b
 
2
 
m (34) fol-
lowed by SDS-PAGE analysis. cDNA made from mRNA ex-
tracted from these transfectants was used as a template for PCR of
the class I MHC–encoding products, which were sequenced to
further confirm the sequence of the appropriate MHC product in
each transfectant.
 
Cytotoxicity Assays.
 
The cytolytic activity of NK lines and
clones against various target cell lines and transfectants was as-
sessed in 5-h 
 
35
 
S-release assays as described (28). Assays were per-
formed in duplicate or triplicate, and data values differed by
 
,
 
10% (and on average, 
 
z
 
5%) of the mean. In all presented cyto-
toxicity assays, the spontaneous release of 
 
35
 
S was 
 
,
 
25% (and on
average, 
 
z
 
10%) of the maximal release.
 
NK Cell Lines and Clones and mAbs.
 
NK cell lines 986, I, 264,
268, and 532 were prepared from healthy donors as described
(28). NK cell lines 15, 26, 53, 60, 69, 71, 86, and X1 were pre-
pared from cells derived from healthy donors sorted to be
CD56
 
1
 
CD3
 
2
 
 by flow cytometry and plated at 30 cells/well
(FACStar
 
PLUS®
 
; Becton Dickinson). These sorted cells were
grown in X-Vivo 10 medium (Bio-Whittaker) supplemented
with 0.1% PHA (Murex), 100 U/ml rIL-2 (Boehringer Mann-
heim), 10% lymphocult (Biotest), 5% human serum (Bio-Whit-
taker), 100 mM MEM sodium pyruvate (Life Technologies), 1%
MEM nonessential amino acids (Life Technologies), 1% 2-ME
(Life Technologies), and 50,000/well irradiated PBLs from two
allogeneic donors and 10,000/well irradiated RPMI 8866. These
sorted cells were restimulated with irradiated feeder cells once ev-
ery 14 d. All NK lines and clones were periodically monitored to
be CD3
 
2
 
 and CD56
 
1
 
 by antibody staining. NK cell cytotoxicity
assays were performed at least 4 d after restimulation with feeder
cells or fresh rIL-2 and were performed using only cells that ap-
peared healthy through a standard laboratory microscope.
mAb to NKIR1, EB6, and HP3E4 were purchased from Immu-
notech or were a gift from M. Lopez-Botet (Hospital Universitario
de la Princesa, Madrid, Spain), respectively. mAb HP3E4 and EB6
both recognize p58 NKIR and can block NK cell recognition of
HLA-C alleles belonging to group 1, including HLA-Cw6 and
-Cw4, but can recognize serologically distinct epitopes (35–37). mAb
recognizing other proteins were used as follows: HLA-C (L31; a gift
from P. Giacomini and A.G. Siccardi, San Raffaele Scientific Insti-
tute, Milan, Italy), NKB1 (DX9; a gift from L. Lanier, DNAX), CD3
(SK7; Becton Dickinson), CD20 (2H7; PharMingen), CD45 (HI30;
PharMingen), CD53 (HI29; PharMingen), CD56 (NCAM16.2;
Becton Dickinson), CD81 (JS-81; PharMingen), CD82 (50F11;
PharMingen), CD94 (HP3D9; PharMingen), HLA-A, B, C (G46-
2.6; PharMingen and W6/32; ATCC), 
 
b
 
2
 
m (BBM.1; ATCC),
HLA-DR (G46-6; PharMingen), IL-2R 
 
g
 
 chain (38024.11; R & D
Systems, Inc.). For mAb blocking of NKIR1 and CD94, TEPC183
(Sigma Chemical Co.) and GL183 (mAb to NKIR2; Coulter Im-
munology) were used as control IgM and IgG1 mAb, respectively.
 
Results
 
The COOH-terminal Portion of HLA-C Is a Determinant in
Inhibition of NK Cell Cytotoxicity.
 
The Bsu36I restriction en-
zyme site in exon 4 of class I MHC genes was used to con-
struct plasmids encoding chimeric proteins of HLA-Cw6
and -Cw7 attached to most of the 
 
a
 
3, transmembrane, and
cytoplasmic domains of HLA-G, termed HLA-Cw6/G end
and HLA-Cw7/G end, respectively (Fig. 1). These chimeric
proteins were expressed in the HLA-A,B,C–negative B cell
line 721.221 and compared with wild-type HLA-Cw6 and
-Cw7 proteins for their capacity to inhibit lysis by various
NK cell lines (Fig. 2).
NK lines 986 and I (and four other lines not shown), in-
dependently derived from healthy donors, efficiently lysed
721.221 cells at the E/T ratios shown but were inhibited
by target cell expression of either HLA-Cw6 or -Cw7. NK
line 986, but not line I, was also inhibited by target cell ex-
Figure 2. The COOH-terminal portion of HLA-C is a determinant
for inhibition of NK cell cytotoxicity. NK cell lines 986 (A) and I (B), se-
lected by their susceptibility to inhibition by the expression of HLA-C
proteins in 721.221 cells, were assayed for their capacity to be inhibited
by expression of HLA-Cw6/G end and HLA-Cw7/G end at various E/T
cell ratios. The data set shown is representative of three independent ex-
periments using two or three independently transfected target cell lines
for each class I MHC protein variant, except HLA-Cw7 and -G, for
which only one transfectant was used. 
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pression of HLA-G. However, neither of these lines (or the
four other lines not shown) was inhibited by target cell ex-
pression of HLA-Cw6/G end or -Cw7/G end (Fig. 2).
 
The Cytoplasmic Tail of HLA-C Is Not a Determinant in Inhi-
bition of NK Cell Cytotoxicity.
 
HLA-G has a short, 6–amino
acid cytoplasmic tail compared with the 33–amino acid cy-
toplasmic tail of HLA-C. Thus, transfectants were made
expressing mutants of HLA-Cw6 in which the cytoplasmic
tail was truncated by the insertion of stop codons at the
various positions marked in Fig. 1. NK lines 268 and 264,
derived from healthy donors, with phenotypes of inhibi-
tion like lines 986 or I in Fig. 2, were also efficiently inhib-
ited by expression of HLA-Cw6 truncated at positions Lys
315, Ser 325, Ser 332 (not shown), and Ser 335 (Fig. 3).
Thus, the cytoplasmic tail after residue 314 can be removed
from HLA-Cw6 with no effect on its capacity to inhibit
NK cell cytotoxicity.
 
The Transmembrane Sequence and, in Particular, Cysteine at
Position 309 of HLA-C Has a Critical Role in Inhibition of NK
Cell Cytotoxicity.
 
To further investigate the sequence of
HLA-Cw6 between residues 201 (the Bsu36I cleavage site)
and 315 that, when replaced by that of HLA-G, incapacitates
the HLA-Cw6 inhibition of NK cell cytotoxicity, a trans-
fectant expressing HLA-Cw6 with the transmembrane se-
quence of HLA-G (HLA-Cw6/TM G) was made. Similarly,
as the most striking difference between the transmembrane
sequences of HLA-Cw6 and HLA-G is at position 309, a
transfectant expressing HLA-Cw6 with cysteine at position
309 mutated to tryptophan (HLA-Cw6/C309W), the corre-
sponding residue present in HLA-A and -G, was also made.
25/37 (68%) NK lines were inhibited by target cell expres-
sion of HLA-Cw6 but efficiently lysed target cells expressing
HLA-Cw6/TM G or HLA-Cw6/C309W (six representative
lines shown, Fig. 4). Some of the other 12 NK lines inhibited
by target cell expression of HLA-Cw6 partially lysed target
cells expressing HLA-Cw6/TM G or -Cw6/C309W. Thus,
the transmembrane sequence and, in particular, cysteine at
position 309 are critical determinants of the capacity of
HLA-Cw6 to inhibit the cytotoxicity of many NK cell lines.
 
The Subset of NK Clones that Stain Brightly with mAbs EB6
and HP3E4 Is Not Sensitive to the Transmembrane Sequence of
HLA-Cw6.
 
To investigate which NK cells are sensitive
Figure 3. The cytoplasmic tail of HLA-Cw6 is not a determinant in
inhibition of NK cell–mediated lysis. NK cell lines 268 (A) and 264 (B),
selected by their susceptibility to inhibition by target cell expression of
HLA-Cw6, were assayed for their capacity to be inhibited by target cell
expression of HLA-Cw6 with truncations placed along various positions
in the cytoplasmic tail. Assays were performed at various E/T cell ratios
shown. Data sets shown are representative of three independent experi-
ments for each NK line. Another independently made transfectant for
HLA-Cw6/315 stop behaved similarly. A transfectant expressing HLA-
Cw6 with a stop codon placed at position 332 behaved similarly to other
truncated -Cw6 transfectants.
Figure 4. The transmembrane sequence, and particularly cysteine at
position 309, controls the capacity of HLA-Cw6 to inhibit lysis by some
NK cell lines. Various arbitrarily numbered NK lines selected by their
susceptibility to inhibition by target cell expression of HLA-Cw6 were
assayed for their capacity to be inhibited by target cell expression of HLA-
Cw6 with the transmembrane sequence replaced by that of HLA-G
(HLA-Cw6/TM G) or the cysteine at position 309 replaced by tryp-
tophan (HLA-Cw6/C309W). Lysis was assayed at the E/T ratio of z3:1,
and at least two independent experiments were performed for each NK
line. Two other independently made transfectants of HLA-Cw6/TM G
gave similar results. The transfectant expressing HLA-Cw6/G end be-
haved similarly to that expressing -Cw6/TM G or -Cw6/C309W with
all NK lines tested (not shown). 
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to the transmembrane sequence of HLA-Cw6, many NK
clones were examined. Three phenotypes of inhibition are
illustrated in Fig. 5. NK clone 4 was efficiently inhibited by
target cell expression of HLA-Cw6, -Cw6/TM G, and
-Cw6/C309W (Fig. 5 A). NK clone 2 was efficiently in-
hibited by expression of HLA-Cw6 but not significantly
inhibited by expression of HLA-Cw6/TM G or -Cw6/
C309W (Fig. 5 B). NK clone 82 was partially inhibited by
target cell expression of HLA-Cw6 yet was unaffected by tar-
get cell expression of HLA-Cw6/TM G or -Cw6/C309W
(Fig. 5 C). In total, 33/145 (23%) NK clones selected for
their ability to be inhibited by target cell expression of
HLA-Cw6 behaved similarly to NK clones 2 or 82 (Fig. 5,
B and C), i.e., they were not inhibited by target cell ex-
pression of HLA-Cw6/TM G or -Cw6/C309W. 112/145
(77%) NK clones behaved similarly to NK clone 4 (Fig.
5 A) in that they could be efficiently or partially inhibited
by target cell expression of HLA-Cw6, -Cw6/TM G, or
-Cw6/C309W. One rare NK clone was even costimulated
by target cell expression of HLA-Cw6 but not by expres-
sion of -Cw6/TM G or -Cw6/C309W (not shown). Also,
many of the NK clones found to be inhibited by target cell
expression of HLA-Cw7 efficiently lysed target cells ex-
pressing HLA-Cw7/G end (not shown), implying that the
importance of the transmembrane sequence in NK cell in-
hibition is not restricted to HLA-Cw6.
Figure 5. NK clones inhibited by target cell expression of HLA-Cw6
differ in their sensitivity to the transmembrane sequence of the protective
class I MHC protein. NK clone 4 (A), NK clone 2 (B), and NK clone 82
(C), selected by their susceptibility to be inhibited by target cell expres-
sion of HLA-Cw6, were assayed for lysis of HLA-Cw6/TM G and
-Cw6/C309W transfectants at the various E/T cell ratios shown. Data
sets shown are representative of two independent experiments performed.
Another independently made HLA-Cw6/TM G transfectant gave similar
results (not shown). The transfectant expressing HLA-Cw6/G end be-
haved similarly to that expressing -Cw6/TM G or -Cw6/C309W (not
shown).
Figure 6. Staining NK clones with mAbs to NK receptors reveals dis-
tinct phenotypes between clones that are sensitive to the transmembrane
sequence of HLA-Cw6 and those that are not. Histograms of fluores-
cence intensity of NK clones stained with EB6 (thick gray line), HP3E4
(dotted line), and no first antibody (thin black line), followed by FITC-
labeled goat anti–mouse Ig secondary antibody. 
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Some of the NK clones that were inhibited by HLA-
Cw6 were phenotyped by mAb staining. All of those tested
were CD3
 
2
 
 and CD56
 
1
 
, as used in the selection, and hap-
pened to be GL183
 
2
 
 (mAb for NKIR2) and DX9
 
2
 
 (mAb
for NKB1). However, they varied considerably in their
expression of NKIR1, being either EB6
 
bright
 
/HP3E4
 
bright
 
(clone 84), EB6
 
dim
 
/HP3E4
 
dim
 
 (clone G), EB6
 
2
 
/HP3E4
 
2
 
(clone 57) (Fig. 6), or EB6
 
2
 
/HP3E4
 
dim
 
 (clones 2 and 82;
Table I). Strikingly, clones inhibited by target cell expres-
sion of HLA-Cw6, -Cw6/TM G, or -Cw6/C309W were
bright for both mAbs EB6 and HP3E4, whereas those in-
hibited by target cell expression of HLA-Cw6 and not by
target cell expression of -Cw6/TM G or -Cw6/C309W
were negative or dim for EB6 or HP3E4 (Table I). Fur-
thermore, only those clones bright for EB6 and HP3E4
were also able to be inhibited by target cell expression of
HLA-Cw4, as expected by the specificity of the NKIR1
(data not shown).
 
Reversal of NK Cell Inhibition by mAb to NK Receptors.
 
To directly determine the NK receptors that facilitate inhi-
bition of clones by target cell expression of HLA-Cw6, the
effect of blocking NKIR and CD94 with mAb HP3E4
and HP3D9, respectively, was assayed. Two representative
clones are shown (Fig. 7). NK clone 15 was efficiently
inhibited by target cell expression of either HLA-Cw6,
-Cw6/TM G, or -Cw6/C309W, and this inhibition could
be efficiently blocked by mAb HP3E4 to NKIR1 and not
by mAb HP3D9 to CD94. In contrast, NK clone X1 effi-
ciently lysed target cells expressing HLA-Cw6/TM G or
-Cw6/C309W, and in this case, the inhibition mediated by
expression of HLA-Cw6 was unaffected by mAb to either
NKIR1 or CD94. This implies that an NK receptor other
than NKIR1 or CD94 mediates inhibition dependent upon
the transmembrane sequence of HLA-Cw6.
 
Discussion
 
The attachment of the COOH-terminal portion of
HLA-G after conserved codon Arg 201 renders the 
 
a
 
1 and
 
a
 
2 extracellular domains of HLA-Cw6 or -Cw7 ineffective
at inhibition of 25/37 NK cell lines. Thus, cell surface ex-
pression of the extracellular domains of an appropriate
HLA-C protein is not sufficient for inhibition of NK cell–
mediated lysis. Unexpectedly, the transmembrane sequence,
and particularly Cys 309, was found to be critical in facili-
tating HLA-Cw6–mediated inhibition of cytotoxicity of
many NK cell lines.
68% (25/37) of NK lines, yet only a smaller subset of NK
clones, i.e., 33/145 (23%), were sensitive to the transmem-
brane sequence of HLA-Cw6. This apparent discrepancy
may be because (a) clones are not a proportionate representa-
tion of cells within a line, i.e., a selection occurs during the
cloning procedure; (b) a selection occurs by the use of NK
lines that were inhibited by HLA-Cw6, and the clones used
were not necessarily obtained from lines that were inhibited
by HLA-Cw6; or (c) a minority of cells within an NK cell
line can dominate the overall cytotoxicity of the line
through secretion of inhibitory or costimulating cytokines or
another method of intercellular communication.
All EB6/HP3E4 NKIR1
 
1
 
 NK clones recognized HLA-
Cw6 independently of the transmembrane sequence (Table I
and Fig. 7 A). However, inhibition of EB6
 
2
 
/HP3E4
 
2
 
 or
 
Table I.
 
Relative Intensity of Staining NK Clones by Antibodies Listed with Corresponding Percent Lysis of 721.221 Cells and Transfectants 
at an E/T Cell Ratio of 
 
z
 
3:1
 
Percent lysis of each transfectant Antibody staining of NK clone (arbitrary units)
NK clone 221 221-Cw6 221-Cw6/C309W No mAb HP3E4 EB6
B 56 5 10 2 100 175
F 40 0 4 3 81 135
H 57 2 13 3 86 87
18 26 11 4 3 67 184
35 27 11 2 3 67 170
95 58 6 8 4 111 125
84 45 1 5 3 165 124
4 39 1 3 2 115 593
23 7 6 2 8 2 2 9 4
82 32 16 29 2 48 6
57 57 23 46 4 4 4
59 59 11 45 4 4 3
64 22 6 21 3 3 3
67 57 25 50 4 4 4
G 42 25 36 3 19 8 
1271
 
Davis et al.
 
EB6
 
dim
 
/HP3E4
 
dim
 
 NK clones by HLA-Cw6 was clearly
dependent on the transmembrane region and particularly
on Cys 309. This inhibition is unlikely to function through
the CD94/NKG2/HLA-E interaction, as there was no cor-
relation between NK lines and clones that were sensitive to
the transmembrane sequence of HLA-Cw6 and those for
which inhibition could be reversed by anti-CD94 mAb
(Fig. 7 B). Moreover, the same leader peptide that facili-
tates HLA-E expression (16–18) is encoded within each
HLA-Cw6 construct. Thus, the NK receptor responsible
for recognition dependent upon the transmembrane sequence
of HLA-Cw6 is unknown. It may be a previously cloned
receptor such as a member of the ILT/LIR family (10–12),
or it could be an uncloned receptor such as that postulated
to associate with NKIR via zinc (38). Allogeneic T cell
lines that lyse 721.221 transfectants expressing HLA-Cw6
equally lysed target cells expressing -Cw6/TM G or -Cw6/
C309W (data not shown), implying that these receptors do
not function on the bulk of T cells.
A glycosylphosphatidylinositol (GPI)-linked variant of
the mouse class I MHC protein, H-2D
 
d
 
, in H-2
 
b
 
 tumor
cells was sufficient to protect against rejection by NK cells
after transplantation (39). Thus, replacement of the trans-
membrane and cytoplasmic domains of this class I MHC
protein with GPI does not affect the capacity of the mouse
class I MHC protein to protect against NK cell cytotoxic-
ity. The apparent discrepancy between this finding and the
current work may be accounted for in several ways: (a) the
GPI linkage and subsequent association of cytoplasmic ty-
rosine kinases (40) facilitates signaling within the target cell
that may converge with the natural transmembrane-medi-
ated signal pathway; (b) the GPI linkage causes similar cell
surface localization/clustering that the cysteine-containing
transmembrane sequence facilitates; or (c) the repertoire of
inhibitory ligands on mouse NK cells is different from that
expressed on human NK cells, and mouse NK cell recep-
tors are less or not at all sensitive to the transmembrane se-
quence of the inhibitory MHC protein.
Aspects of class I MHC protein expression that may be
altered by mutation of the transmembrane sequence in-
clude: (a) oligomerization (41, 42); (b) association with an-
other protein on the target cell surface (43–46); (c) expres-
sion of a protein associated in transport; (d) particular
localization within cell membrane domains, perhaps facili-
tated by bound palmitic acid (47, 48); (e) conformational
change, perhaps induced by association of particular lipids
(49); or (f) capacity for internalization of protein from the
cell surface (29). However, dimerized or oligomeric class I
MHC protein at the cell surface was not detected by im-
munoprecipitating surface-biotinylated class I MHC pro-
tein from HLA-Cw6 or -Cw6/TM G transfectants, and no
evidence was found of a second specific protein component
in the immunoprecipitated material (data not shown). More-
over, confocal fluorescence microscopy failed to reveal any
change in the surface or intracellular localization of HLA-
Cw6 with an altered transmembrane sequence (data not
shown). However, this does not rule out the possibility that
the transmembrane sequence is critical in facilitating tran-
sient dimerization of HLA-Cw6 or association with another
protein upon ligation of an NK receptor.
Cysteine at position 309 of class I MHC proteins is most
likely located at the interface of the inner leaflet of the lipid
bilayer and cytoplasm where the local environment is
probably not dissimilar to the extremely viscous surfactant/
aqueous interface widely studied in model colloidal systems
such as lipid vesicles and micelles (50, 51). The unique
physical conditions of the interfacial environment may be
critical to the molecular mechanism by which the cysteine
facilitates some aspect of class I MHC protein presentation
through noncovalent interactions. For example, the trans-
membrane sequence may control the lateral mobility of
class I MHC protein within the cell membrane.
Figure 7. NK clones inhibited by target cell expression of HLA-Cw6
differing in their sensitivity to the transmembrane sequence of the protec-
tive class I MHC protein also differ in their sensitivity to blocking by
mAb HP3E4. NK clone 15 (A) and NK clone X1 (B), selected by their
susceptibility to inhibition by target cell expression of HLA-Cw6, were
assayed for lysis of HLA-Cw6/TM G and -Cw6/C309W transfectants at
the E/T cell ratio of 3:1 in the presence and absence of mAb HP3E4
(anti-NKIR1), as ascites diluted 1:1,000, and 20 mg/ml anti-CD94 mAb.
Isotype control mAb TEPC183 (IgM ascites control for HP3E4) and
GL183 (IgG1 control for CD94) had no effect on the NK cell lysis of any
of the target transfectants (not shown). Data sets shown are representative
of two independent experiments performed. Several other NK lines and
clones behaved similarly to those shown. Inhibition of a minor subset of
NK lines and clones by target cell expression of HLA-Cw6 could be
blocked by anti-CD94 mAb with no correlation to whether or not each
particular NK line or clone could be inhibited by target cell expression of
HLA-Cw6/TM G or -Cw6/C309W (not shown). 
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In summary, a critical physiological function for the
transmembrane sequence of class I MHC proteins in its in-
teraction with a subset of NK cells has been shown. A cys-
teine within this transmembrane sequence located at or near
the interface of the inner leaflet of the lipid bilayer and cy-
toplasm is particularly important. This cysteine is present in
HLA-B and -C proteins but not in HLA-A, -G, -E, -F or
CD1a, b, c, or d (although CD1d has a cysteine located
centrally within the transmembrane region). HLA-B and
-C are major ligands for NKIR, and it is thus intriguing to
wonder whether the presence of a cysteine at this location
was conserved specifically to facilitate some aspect of NK
cell recognition.
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